Compare OGI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGI | ADCT |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.5M | 136.1M |
| IPO Year | 2015 | 2019 |
| Metric | OGI | ADCT |
|---|---|---|
| Price | $0.88 | $1.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.44 | ★ $3.33 |
| AVG Volume (30 Days) | 414.5K | ★ 1.6M |
| Earning Date | 12-15-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | $34.95 | N/A |
| Revenue Next Year | $30.97 | $25.32 |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $0.85 | $0.78 |
| 52 Week High | $2.24 | $4.98 |
| Indicator | OGI | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 36.55 | 53.54 |
| Support Level | N/A | $1.01 |
| Resistance Level | $0.96 | $1.87 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 11.97 | 32.18 |
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).